Treatable risk factors included anemia in 40% of patients, and elevated total plasma homocysteine or homozygosity for the t-MTHFR mutation in 21%.

• 可治疗的风险因子包括40%25病患有贫血症，21%25的人血浆中同型半胱氨酸升高或有t-MTHFR突变的同质性。